Synovial Histology in CPPD Disease and the Impact of Therapy on Synovial Inflammation: Interim Results of a Phase II Randomized Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1842; Pres time: Nov 9, 2026; 09:00 AM - 09:15 AM; Location: W206; In Person; "Eligible patients fulfilling the 2023 ACR/EULAR CPPD criteria are randomized to baricitinib 4 mg/day or investigator-selected SOC (one or a combination of colchicine, methotrexate, hydroxychloroquine, corticosteroids or NSAIDs). This interim analysis provides the first description of CPPD synovium, identifying three patterns: highly inflammatory, intermediate, and fibrotic. In such a clinically multifaceted disease, histologic characterization could offer crucial pathogenic insights to guide new therapies. Treatment efficacy depends on baseline inflammation, with histological improvements occurring exclusively in high-grade synovitis."
Clinical • P2 data • Cardiovascular • Fibrosis • Hematological Disorders • Inflammation • Inflammatory Arthritis • Retinal Vein Occlusion • Rheumatoid Arthritis • Thrombosis • CD20 • CD68 • CD8
|
|
Laura Pezzoni1; Paola Maroni2; Lene Terslev3; Veronica Sansoni4; Davide Rozza5; Daniele Cirillo1; Marco Dal Fabbro6; Rodolfo Fabbri1; Alessandro Lucia7; Dimitris Katsifis-Nezis8; Piercarlo Sarzi Puttini9; Silvia Sirotti10; Greta Pellegrino11; Lucia Sciamanna12; Luigi Zagra12; Giovanni Lombardi13; Georgios Filippou14
|